NCT01596855已完成2 期
A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- FibroGen
- 入组人数
- 96
- 试验地点
- 9
- 主要终点
- Hemoglobin maintenance using FG-4592 dosing regimen in ESRD subjects. Number of subjects who hemoglobin levels are maintained at no lower than 0.5 g/dL below their mean baseline value during weeks 6 and 7.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on maintenance hemodialysis and receiving epoetin alfa.
详细描述
Dose ranging study with three consecutive dose escalation cohorts. The study objectives are to demonstrate that FG-4592 is effective in maintaining hemoglobin (Hb) levels when converting from epoetin alfa and to establish optimum starting doses and dose adjustment regimens for Hb maintenance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has voluntarily signed and dated an informed consent form
- •Age 18 to 75 years
- •End-stage renal disease (ESRD) and receiving maintenance hemodialysis TIW for ≥4 months prior to Day 1
- •Hemoglobin (Hb) values in 4 screening visits and the mean Hb must be between 9.0 and 12.0 g/dL (inclusive), and the difference between them must be ≤1.5 g/dL.
- •Stable doses of IV or Subcutaneous injection of epoetin alfa, defined as follows:
- •Epoetin alfa dose range for 6 weeks prior to Day -7:
- •3000 to 20,000 IU/week
- •Stable doses of epoetin alfa (i.e., the maximum epoetin alfa dose does not exceed 130% of the lowest dose of epoetin alfa taken in this period)
- •Complete Blood Count (CBC), Hematology, liver function blood tests within acceptable limits
- •Serum folate and vitamin B12 levels above the lower limit of normal (LLN)
- •Body weight: 40 to 100 kg (dry weight) inclusive
- •Body mass index (BMI): 16 to 38 kg/m2 inclusive
- •HD subjects: dialysis vascular access via native arteriovenous fistula or synthetic graft (not via catheter)
排除标准
- •Anticipated change in hemodialysis prescription or access during the screening or dosing period of the study
- •Any clinically significant infection or evidence of an underlying infection such as a white blood cell count (WBC) > ULN during screening on two separate occasions,
- •Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B surface antigen (HBsAg); anti-hepatitis C virus antibody (anti-HCV Ab)
- •History of chronic liver disease
- •New York Heart Association Class III or IV congestive heart failure
- •Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
- •Active or chronic gastrointestinal bleeding, or a known coagulation disorder
- •Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.)
- •Hematological disorders, including myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia
- •History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric
- •Active hemolysis or diagnosis of hemolytic syndrome
- •Known bone marrow fibrosis
- •Uncontrolled or symptomatic secondary hyperparathyroidism (PTH>600ng/L)
- •Any prior organ transplantation
- •Drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal condition that may lead to reduced absorption of study drug
- •History of alcohol or drug abuse; or a positive drug screen for a substance that has not been prescribed for the subject
- •Prior treatment with FG-4592
- •Use of traditional Chinese medicines (TCM) during the screening visit to Day 1 or plans to use TCM during the study unless approved in advance by the Medical Monitor
研究组 & 干预措施
FG-4592
Experimental
Active Drug
干预措施: FG-4592 (Drug)
Epoetin alfa
Active Comparator
Standard of care
干预措施: Epoetin Alfa (Drug)
结局指标
主要结局
Hemoglobin maintenance using FG-4592 dosing regimen in ESRD subjects. Number of subjects who hemoglobin levels are maintained at no lower than 0.5 g/dL below their mean baseline value during weeks 6 and 7.
时间窗: Week 7
次要结局
- Number (%) of subjects whose hemoglobin levels are between 9.0 and 13.0 g/dL at Weeks 3, 4, 5, 6 and 7.(Week 7)
- Number (%) of subjects whose hemoglobin levels at Weeks 3, 4, 5, 6 and 7 are greater than or equal to their baseline level.(Week 7)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
Study of FG-4592 in Subjects With Chronic Kidney Disease in ChinaAnemia in Chronic Kidney DiseaseNCT01599507FibroGen91
终止
3 期
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)AnemiaNCT03263091FibroGen184
已完成
2 期
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsNon-Hodgkin LymphomaHodgkin DiseaseMultiple MyelomaNCT02104427GPCR Therapeutics, Inc.12
已完成
2 期
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to TaxotereProstate CancerNCT00274287Oncology Specialists, S.C.15
终止
2 期
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)Cognitive Impairment Associated With Schizophrenia (CIAS)NCT02855411Biogen35